New drug combo aims to stop brain lymphoma from returning
NCT ID NCT04627753
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a two-year maintenance treatment with lenalidomide and rituximab can prevent relapse in patients with primary central nervous system lymphoma who have responded to initial chemotherapy but are not eligible for a stem cell transplant. The study will enroll 30 participants and track how long they live without the cancer progressing. The goal is to improve survival in a group that currently has very poor outcomes after relapse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenalidomide and rituximab (drugs)
What this could lead to
If successful, this maintenance therapy could help prevent relapse and extend survival for patients with primary CNS lymphoma who cannot undergo a stem cell transplant.
What could go wrong
This is a small, early-phase study (30 participants) with no control group. The drugs may cause side effects, and it is not yet known if they will meaningfully improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CNS LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, 135710, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact